Business
CSL (ASX:CSL) share price hit by broker downgrade

The CSL Limited (ASX: CSL) share price was a positive performer on Thursday.
The biotherapeutics company’s shares charged 3% higher to end the day at $289.00.
Why did the CSL share price charge higher?
Investors were buying CSL shares following the release of a strong half year result.
For the six months ended 31 December, the company delivered a 16.9% increase in revenue over the prior corresponding period to US$5,739 million.
This was driven largely by a 38% jump in Seqirus revenue, thanks to a 44% increase in seasonal influenza vaccine sales. Demand for flu vaccines has been exceptionally strong due to the COVID-19 pandemic.
Also supporting the company’s growth was its CSL Behring business, which reported a 9% increase in…
-
Business16 hours ago
This ASX 200 healthcare stock crashed 14% to 4-year low. Here’s what happened
-
Business12 hours ago
Dicker Data rides the AI trend to double digit growth
-
Business20 hours ago
This leading broker thinks the CSL share price can climb 40%
-
Noosa News20 hours ago
Old Translink app canned, and new version ‘worse than paper map from 2015’